Newsroom

JDRF, our partners and our research funding make headlines. Read about our leading role in breakthrough advances that improve lives for people with type 1 diabetes (T1D).

Recent Press Releases

JDRF Official Statement on Vertex Pharmaceutical’s Clinical Trial for VX-880 Results Announcement

October 18, 2021

Read More about JDRF Official Statement on Vertex Pharmaceutical’s Clinical Trial for VX-880 Results Announcement
vTv Therapeutics Announces Positive Results from Mechanistic Study Indicating No Increased Risk of Ketoacidosis with TTP399 during Acute Insulin Withdrawal in Patients with Type 1 Diabetes

October 12, 2021

Read More about vTv Therapeutics Announces Positive Results from Mechanistic Study Indicating No Increased Risk of Ketoacidosis with TTP399 during Acute Insulin Withdrawal in Patients with Type 1 Diabetes
JDRF Awards New Grant to Explore Cognitive Behavioral Therapy to Reduce Diabetes Distress

September 30, 2021

Read More about JDRF Awards New Grant to Explore Cognitive Behavioral Therapy to Reduce Diabetes Distress
JDRF Announces the Addition of Shia Learns About Insulin book into the Bag of Hope

September 15, 2021

Read More about JDRF Announces the Addition of Shia Learns About Insulin book into the Bag of Hope
Raise Awards Honors Nonprofits Shaping the Future of Fundraising

September 14, 2021

Read More about Raise Awards Honors Nonprofits Shaping the Future of Fundraising

View All

Newsroom

Recent Press Releases

JDRF Official Statement on Vertex Pharmaceutical’s Clinical Trial for VX-880 Results Announcement

vTv Therapeutics Announces Positive Results from Mechanistic Study Indicating No Increased Risk of Ketoacidosis with TTP399 during Acute Insulin Withdrawal in Patients with Type 1 Diabetes

JDRF Awards New Grant to Explore Cognitive Behavioral Therapy to Reduce Diabetes Distress

JDRF Announces the Addition of Shia Learns About Insulin book into the Bag of Hope

Raise Awards Honors Nonprofits Shaping the Future of Fundraising

Your privacy